english.prescrire.org > Prescrire International > N°157 - February 2015

n°157

February 2015

Issue Contents
Editorial

Free  To serve patients

p.32
A two-way exchange of information

Marketing Authorisations

Canagliflozin (Invokana°)

p.33-35
A "me-too" of the dangerous dapagliflozin

Sodium phenylbutyrate coated granules (Pheburane°)

p.35-36
Defective urea synthesis: a welcome formulation

Cholic acid (Orphacol°)

p.36-37
Decisive in some hereditary bile acid deficiencies

In brief: hereditary defects of primary bile acid synthesis type 1 and type 2

p.37

Imatinib (Glivec°) and acute lymphoblastic leukaemia in children

p.38-39
Prolonged survival in Philadelphia chromosome-positive cases

INN common stem: -pris-

p.39

Aflibercept (Eylea°) and retinal vein occlusion

p.40
No proven advantages but many uncertainties

Adverse Effects

Drugs that promote dental caries

p.41-44
Psychotropics, sugar-containing medicines, etc.

Tooth decay

p.43

Choosing not to take bromocriptine

p.45
Results of a survey in a maternity clinic

Pregabalin: major weight gain

p.45
Up to 20 kg

Hospital readmission for adverse drug reactions

p.46
Sometimes the same drug and same adverse effects

Acute pancreatitis linked to isotretinoin

p.46
Cases reported in France

Reviews

Prevention of migraine attacks

p.47-48
First-choice treatments

Free  Sciatica and epidural corticosteroid injections

p.49
No evidence of efficacy

Outlook

The reorganisation of European pharmacovigilance

p.50-54
Part 2: From spontaneous reports to agency reviews and decisions

Encouraging spontaneous reporting of adverse effects

p.53
Editors' Opinion

Lead exposure: no known safe dose

p.55
Reduction of exposure in children and pregnant women is essential

Masthead

Free  Masthead

p.30

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe